Product/Composition:- | Nizatidine capsules |
---|---|
Strength:- | 150 mg |
Form:- | Capsules |
Reference Brands:- | Axid(US & EU) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Nizatidine capsules are H2-receptor antagonists that block histamine effects on gastric acid secretion in the stomach lining. They reduce gastric acid production, alleviating acid reflux, ulcers, and GERD symptoms. Benefits include symptom relief, mucosal healing, and prevention of ulcer complications, supporting gastrointestinal health effectively.
Nizatidine capsules, marketed as Axid, are approved in the US by the FDA and in the EU via EMA for treating gastric ulcers, GERD, and Zollinger-Ellison syndrome. Regulatory approval requires comprehensive dossiers including clinical efficacy, safety data, manufacturing standards, and pharmacovigilance plans. The FDA reviews clinical trial and quality data for timely approval, while the EMA ensures compliance with regional safety and manufacturing standards. For detailed guidance on dossier preparation, regulatory pathways, and market access, visit PharmaTradz. Proper adherence supports swift approval, safe use, and global availability of nizatidine capsules, helping improve gastrointestinal health and prevent ulcer complications worldwide.